Jin Medical agrees US$159.42 million VIE control deal for Huaxia Qiying assets

Jin Medical entered a Sept. 8, 2026 deal to take contractual control of Huaxia Qiying via a VIE structure.

Consideration totals USD 159.42 million, payable at closing through issuance of 71,282,488 Class A ordinary shares.

Target assets center on ginseng bio-resources, research data, rare ginsenosides, and the KB-120 fermentation technology platform.

Huaxia Qiying has no established commercial operations; assets are intended to support future commercialization and business development.

The transaction also includes related asset, equity, and receivable transfers, with a potential 622,123-share fallback tied to a delayed equity transfer.